Clinical trial
A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris
NCT00995969 is registered in ClinicalTrials.gov with Creabilis SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris
- Lead sponsor
- Creabilis SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2010
- Completion date
- January 31, 2011
- Enrollment
- 58 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.